technology
PushButton AI Team ·
Pharma just burned billions betting AI on the wrong part of the process. 150 companies threw money at molecule design — the sexy, visible part. Meanwhile, the real bottleneck (clinical trials, regula
Pharma just burned billions betting AI on the wrong part of the process.
150 companies threw money at molecule design — the sexy, visible part. Meanwhile, the real bottleneck (clinical trials, regulatory approvals) stayed completely broken. Faster molecule design didn't speed anything up.
Sound familiar?
You've probably bought the tool that looked impressive in the demo. The one your team opened twice, then quietly stopped using. $200/month going nowhere. That's not stupidity — that's what happens when vendors sell solutions before anyone diagnoses the actual problem.
The lesson from pharma's expensive mistake is simple.
AI doesn't create value by being applied to what looks complicated. It creates value when applied to what's actually slowing you down. Most business owners skip the diagnosis and jump straight to the purchase. That's where the money disappears.
Here's your one action this week.
Write down the single task that eats the most time in your business right now. Not the flashiest problem. The grinding, repetitive one. That's your first AI target — and it's almost always solvable with tools you already have access to.
What's the most overhyped AI promise someone sold you that didn't survive contact with your actual business?
#AIStrategy #SmallBusiness #BusinessGrowth #AIImplementation
By 2022 some 150 firms were applying AI to small-molecule design alone, and the money behind them—a single 2024 entrant, Xaira, launched with $1 ...
